Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

8.700 +0.090 (+1.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
ImmunityBio announced that it has partnered with Biopharma and Cigalah and hopes to launch Anktiva across the broader Middle East and North Africa (MENA) region over time. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug ↗
Traders are closely watching positioning, as short interest hit a record 13.7% of the free float amid a jump in retail activity on Stocktwits this week. 
Via Stocktwits
Topics Government
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs ↗
Via Stocktwits
IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing ↗
Via Stocktwits
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
As of February 19, 2026, ImmunityBio, Inc. (NASDAQ: IBRX) stands at a pivotal crossroads between clinical ambition and commercial reality. Once a "story stock" fueled by the vision of its billionaire... 
Via Finterra
Topics Lawsuit
News headline image
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries ↗
The company also announced the establishment of an Irish subsidiary in Dublin to support its distribution and commercialization strategy across Europe. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Why IBRX Stock Became A High-Stakes Showdown Between Shorts And Retail Bulls ↗
The standoff ended when the EU granted conditional approval, sending shares up 42% on Wednesday. 
Via Stocktwits
News headline image
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer ↗
On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal scrutiny. 
Via The Motley Fool
Topics Initial Public Offering Stocks
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Why ImmunityBio Stock Is Soaring Today ↗
The biopharma outfit's flagship cancer-fighting drug continues to rack up approvals. 
Via The Motley Fool
Discover the most active stocks in Wednesday's session. ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
IBRX Gains 30% On Fresh Approval For Bladder Cancer Drug In EU: Retail, Wall Street Eyes Further Rally ↗
The European Commission granted conditional marketing authorization to ImmunityBio’s Anktiva, implying that it wants more data from the company. 
Via Stocktwits
News headline image
How High Can IBRX Stock Go Now? Here’s What Wall Street Thinks After Saudi Nod For Bladder Cancer Filing ↗
Koyfin data shows an average 12-month target of $11.8, implying a 96% upside from the stock's current levels. 
Via Stocktwits
News headline image
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’ ↗
The Saudi Food and Drug Authority encouraged the company to submit a regulatory filing for its recombinant Bacillus Calmette-Guérin, which the company expects to submit within weeks. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗
Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals ↗
The comments come as ImmunityBio pushes for broader global access to Anktiva across indications. 
Via Stocktwits
News headline image
IBRX Stokes Retail Chatter — Investors See Anktiva Beat Merck’s Keytruda With Approval In EU ↗
Retail investors are now looking forward to a full approval of Anktiva in the EU for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. 
Via Stocktwits
News headline image
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗
On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans. 
Via The Motley Fool
Topics Stocks
News headline image
IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research ↗
Patrick Soon Shiong, ImmunityBio’s founder, took to X on Saturday to clarify what the update signified. 
Via Stocktwits
Topics Death ETFs
Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗
Via Stocktwits
Topics Economy Stocks
News headline image
Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month ↗
Today, Jan. 23, 2026, profit taking and fresh glioblastoma survival data weighed on a soaring biotech stock. 
Via The Motley Fool
Topics Stocks
News headline image
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz ↗
ImmunityBio stated that it has not yet achieved median survival in patients receiving Anktiva + CAR-NK treatment in the trial. 
Via Stocktwits
Topics Death
News headline image
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock. 
Via The Motley Fool
Topics Stocks
News headline image
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer ↗
On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans. 
Via The Motley Fool
Topics Stocks
Which stocks are most active on Tuesday? ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today ↗
Retail sentiment on Stocktwits has flipped bearish on SPY and QQQ amid elevated message volumes and rising volatility. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Why Is ImmunityBio Stock Back In Retail Spotlight Today? ↗
The company outlined progress across multiple cancer programs following last week's series of clinical and regulatory updates. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.